LLY

1,022.7

+0.26%↑

JNJ

246.77

+0.74%↑

ABBV

224.2

-1.89%↓

NVS

163.46

-1.15%↓

MRK

121.78

+0.14%↑

LLY

1,022.7

+0.26%↑

JNJ

246.77

+0.74%↑

ABBV

224.2

-1.89%↓

NVS

163.46

-1.15%↓

MRK

121.78

+0.14%↑

LLY

1,022.7

+0.26%↑

JNJ

246.77

+0.74%↑

ABBV

224.2

-1.89%↓

NVS

163.46

-1.15%↓

MRK

121.78

+0.14%↑

LLY

1,022.7

+0.26%↑

JNJ

246.77

+0.74%↑

ABBV

224.2

-1.89%↓

NVS

163.46

-1.15%↓

MRK

121.78

+0.14%↑

LLY

1,022.7

+0.26%↑

JNJ

246.77

+0.74%↑

ABBV

224.2

-1.89%↓

NVS

163.46

-1.15%↓

MRK

121.78

+0.14%↑

Search

Maravai LifeSciences Holdings Inc (Class A)

Cerrado

3.07 3.72

Resumen

Variación precio

24h

Actual

Mínimo

2.87

Máximo

3.12

Métricas clave

By Trading Economics

Ingresos

44M

-26M

Ventas

-5.8M

42M

Margen de beneficio

-61.388

Empleados

550

EBITDA

44M

-22M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+51.01% upside

Dividendos

By Dow Jones

Próximas Ganancias

25 feb 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

8.3M

1.1B

Apertura anterior

-0.65

Cierre anterior

3.07

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

19 feb 2026, 23:47 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

19 feb 2026, 23:47 UTC

Charlas de Mercado

Nikkei May Decline Amid Caution Over Potential U.S. Strike on Iran -- Market Talk

19 feb 2026, 23:39 UTC

Adquisiciones, fusiones, absorciones

Swiss Re Corporate Solutions to Buy QBE Insurance's Global Trade Credit and Surety Business >SREN.EB

19 feb 2026, 23:38 UTC

Ganancias

Samsung Fire & Marine Insurance 2025 Net KRW2.020T Vs. Net KRW2.077T >000810.SE

19 feb 2026, 23:38 UTC

Ganancias

Samsung Fire & Marine Insurance 2025 Oper Pft KRW2.659T Vs. Pft KRW2.650T >000810.SE

19 feb 2026, 23:38 UTC

Ganancias

Samsung Fire & Marine Insurance 2025 Rev KRW24.779T Vs. KRW22.657T >000810.SE

19 feb 2026, 23:37 UTC

Charlas de Mercado

Gold Edges Lower on Possible Position Adjustment -- Market Talk

19 feb 2026, 23:34 UTC

Ganancias

Samsung Fire & Marine Insurance 4Q Net Profit Missed FactSet-Compiled Consensus

19 feb 2026, 23:34 UTC

Ganancias

Samsung Fire & Marine Insurance 4Q Net KRW234.38B Vs. Net KRW207.88B >000810.SE

19 feb 2026, 23:33 UTC

Ganancias

Samsung Fire & Marine Insurance 4Q Oper Pft KRW391.26B Vs. Pft KRW252.81B >000810.SE

19 feb 2026, 23:33 UTC

Ganancias

Samsung Fire & Marine Insurance 4Q Rev KRW6.083T Vs. KRW6.297T >000810.SE

19 feb 2026, 22:13 UTC

Charlas de Mercado

Goodman's Lack of Earnings Upgrade 'Largely Timing Related' -- Market Talk

19 feb 2026, 22:08 UTC

Ganancias

Fairfax Financial 4Q Rev $8.11B >FFH.T

19 feb 2026, 22:07 UTC

Ganancias

Eldorado Gold 4Q EPS $1.19 >ELD.T

19 feb 2026, 22:06 UTC

Ganancias

Centerra Gold: 2026 Consolidated Gold Production Expected 250,000 to 280,000 Ounces, Copper Production Expected 50M to 60M Pounds >CG.T

19 feb 2026, 22:05 UTC

Ganancias

Eldorado Gold 4Q Adj EPS 63c >ELD.T

19 feb 2026, 22:05 UTC

Ganancias

Eldorado Gold 4Q Rev $577.2M >ELD.T

19 feb 2026, 22:04 UTC

Ganancias

Eldorado Gold 4Q Gold Sales 126,923 Ounces >ELD.T

19 feb 2026, 22:04 UTC

Ganancias

Eldorado Gold 4Q Gold Production 123,416 Ounces >ELD.T

19 feb 2026, 21:50 UTC

Charlas de Mercado
Ganancias

Tech, Media & Telecom Roundup: Market Talk

19 feb 2026, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

19 feb 2026, 21:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

19 feb 2026, 21:43 UTC

Ganancias

St Barbara 1H Underlying Profit A$1.3 Million Vs A$48.1 Million Loss Year Earlier

19 feb 2026, 21:42 UTC

Adquisiciones, fusiones, absorciones

Palo Alto Networks Announces Offer to Purchase Relating to CyberArk Software Ltd.'s 0.00% Convertible Senior Notes Due 2030

19 feb 2026, 21:42 UTC

Ganancias

St Barbara 1H Revenue A$128.8 Million, Up 32% On-Year

19 feb 2026, 21:41 UTC

Ganancias

Correct: St Barbara 1H Net Loss A$249,000

19 feb 2026, 21:40 UTC

Ganancias

St Barbara 1H Net Loss A$249 Million

19 feb 2026, 21:39 UTC

Ganancias

Perseus Mining Reaffirms FY26 Production, AISC Guidance

19 feb 2026, 21:37 UTC

Ganancias

These Stocks Are Today's Movers: Walmart, Occidental, Klarna, Wayfair, Deere, Omnicom, EPAM, and More -- Barrons.com

19 feb 2026, 21:37 UTC

Ganancias

Century Aluminum Expects 1Q Adj EBITDA $215 M to $235 M >CENX

Comparación entre iguales

Cambio de precio

Maravai LifeSciences Holdings Inc (Class A) Esperado

Precio Objetivo

By TipRanks

51.01% repunte

Estimación a 12 meses

Media 4.5 USD  51.01%

Máximo 4.5 USD

Mínimo 4.5 USD

De acuerdo con 2 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Maravai LifeSciences Holdings Inc (Class A) Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

2 ratings

2

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

2.02 / 2.115Soporte y Resistencia

Corto Plazo

Bullish Evidence

Medio plazo

Strong Bullish Evidence

Largo Plazo

No Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
help-icon Live chat